ERBB2 and neoplasm: For instance, according to a recent precision medicine molecular case report, a patient from MYPATHWAY trial diagnosed with mCRC harboring HER2 amplification with concurrent HER2-del16 splice and TP53 missense mutations exhibited an aggressive tumor progression and resistance to trastuzumab and pertuzumab combination therapy [65].